Stayble Therapeutics secures all key data from ongoing Phase IIb study with STA363
Stayble Therapeutics AB ("Stayble" or the "Company") announces today that the Company's Phase IIb study has reached the follow-up goal of 100 patients completing their 6-month visit. As a result, all necessary data to evaluate the study's primary efficacy endpoint has been secured. All patients will continue to be followed until they complete their 12-month visit after which the code will be broken if the treatment is effective. To date, approximately 50 percent of patients have completed their 12-month visit. Top-line data is expected to be presented in Q4 2023.Andreas Gerward, CEO of